Clinical Trial

CS-121 APOC3 Base Editing in FCS

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-12.
Status change: Not Yet Recruiting → Recruiting 2026-02-08
Trial Details
NCT Number NCT07176923
Lead Sponsor CorrectSequence Therapeutics Co., Ltd
Collaborators: The First Affiliated Hospital of Anhui Medical University
Conditions Familial Chylomicronemia Syndrome (FCS)
Enrollment 15 participants
Start Date 2025-10-15
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-11